A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma
Head & Neck · 2025-01 · 47 (1) · 81-89
DOI: 10.1002/hed.27887 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Head & Neck, online erschienen am 29.07.2024. Verfasst von Christopher D Goodman und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Radiosurgery, Esthesioneuroblastoma, Olfactory, Neoplasm Recurrence, Local, Nose Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCR NIH HHS.
Abstract (Originalsprache)
Background
Treatment for dural recurrence of olfactory neuroblastoma (ONB) is not standardized. We assess the outcomes of stereotactic body radiotherapy (SBRT) in this population.
Methods
ONB patients with dural recurrences treated between 2013 and 2022 on a prospective registry were included. Tumor control, survival, and patient‐reported quality of life were analyzed.
Results
Fourteen patients with 32 dural lesions were evaluated. Time to dural recurrence was 58.3 months. Thirty lesions (94%) were treated with SBRT to a median dose of 27 Gy in three fractions. Two patients (3 of 32 lesions; 9%) developed in‐field radiographic progression, five patients (38%) experienced progression in non‐contiguous dura. Two‐year local control was 85% (95% CI: 51–96%). There were no >grade 3 acute toxicities and 1 case of late grade 3 brain radionecrosis.
Conclusion
In this largest study of SBRT reirradiation for ONB dural recurrence to date, high local control rates with minimal toxicity were attainable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
- Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada.
ORCID-Profile: Christopher D Goodman, Adam S Garden, Kevin Diao, Jay Reddy, Michael Spiotto, Clifton D Fuller, Renata Ferrarotto, Shirley Y Su
Förderung
- NIDCR NIH HHS
Zitieren
APA
Goodman, C. D., DeMonte, F., Nguyen, T. P., Garden, A. S., Wang, C. H., Wang, X. A., Diao, K., Lee, A., Reddy, J., Moreno, A., Spiotto, M., Fuller, C. D., Rosenthal, D., Ferrarotto, R., Raza, S. M., Su, S. Y., Warner, A., Hanna, E., & Phan, J. (2025). A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma. Head & Neck, 47(1), 81-89. https://doi.org/10.1002/hed.27887
Vancouver
Goodman CD, DeMonte F, Nguyen TP, Garden AS, Wang CH, Wang XA, et al. A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma. Head & Neck. 2025;47(1):81-89. doi:10.1002/hed.27887
BibTeX
@article{Goodman2025,
author = {Goodman, Christopher D and DeMonte, Franco and Nguyen, Theresa P and Garden, Adam S and Wang, Catherine He and Wang, Xin A and Diao, Kevin and Lee, Anna and Reddy, Jay and Moreno, Amy and Spiotto, Michael and Fuller, Clifton D and Rosenthal, David and Ferrarotto, Renata and Raza, Shaan M and Su, Shirley Y and Warner, Andrew and Hanna, Ehab and Phan, Jack},
title = {A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma},
journal = {Head & Neck},
year = {2025},
volume = {47},
number = {1},
pages = {81--89},
doi = {10.1002/hed.27887}
}
EUVIMED